Raju Kucherlapati, Ph.D. Joins Zyomyx(TM) Board of Directors

Apr 03, 2001, 01:00 ET from Zyomyx, Inc.

    HAYWARD, Calif., April 3 /PRNewswire/ -- Zyomyx, Inc. announced today the
 appointment of Raju Kucherlapati, Ph.D., to its Board of Directors.
     Since 1989, Dr. Kucherlapati has served as Chairman of the Department of
 Molecular Genetics at the Albert Einstein College of Medicine.  In 1993,
 Dr. Kucherlapati assumed additional responsibility as Director of the
 college's Human Genetics Program, which seeks to bring the power of molecular
 genetics to the scientific community.  From 1982 to 1989, Dr. Kucherlapati was
 a Professor at the University of Illinois College of Medicine.  Prior to this
 post, Dr. Kucherlapati served as an Assistant Professor at Princeton
 University.  During his 30-year career as a geneticist, Dr. Kucherlapati has
 participated in the human genome mapping and sequencing effort, contributed to
 the sequencing of the mouse genome and worked to identify genes key to human
 genetic disorders.  He also serves as a member of the National Advisory
 Council of the National Human Genome Research Institute.  Dr. Kucherlapati
 completed his postdoctoral work at Yale University and was awarded a Ph.D. in
 Genetics from the University of Illinois, Urbana.
     Dr. Kucherlapati was a founder of Cell Genesys, Inc. and Millennium
 Pharmaceuticals, Inc., and currently serves as a Director for Abgenix, Inc.,
 Millennium, and Valentis, Inc.  Through a combination of his own research and
 his affiliations with these companies, Dr. Kucherlapati has contributed
 greatly to a number of key advancements in biotechnology and has participated
 in successfully guiding several emerging companies to industry leadership.
     "We are delighted to welcome Dr. Kucherlapati to our Board of Directors,"
 stated Lawrence K. Cohen, Ph.D., Chief Executive Officer of Zyomyx.
 "Dr. Kucherlapati's experience with leading life science companies will assist
 the Company's growth and strengthen its position within the proteomics
 community.  In addition, his expertise in the area of genomics and with the
 technical innovations that advanced that field will provide critical guidance
 as Zyomyx seeks to pioneer new technologies for protein research."
     Located in Hayward, California, Zyomyx, Inc., is bridging the gap between
 genomic information and proteomics through the development of a versatile
 platform technology to innovate protein analysis.  Zyomyx' approach will, for
 the first time, bring to proteomics highly parallel and high throughput
 analysis, capacities that are essential to the advancement of genomics. Zyomyx
 has successfully integrated protein biochemistry with advanced materials
 science and microfabrication to create the first miniaturized biochip
 containing high-density arrays of functional proteins for use in drug
 discovery and diagnosis.  Zyomyx' lead product, the Proteomics Biochip, a
 protein profiling biochip, is designed to accelerate target discovery and
 validation, and has applications throughout the pharmaceutical drug
 development process.  Zyomyx has ongoing partnerships with Fujirebio, Inc.,
 Cambridge Antibody Technology, MDS Proteomics Inc. and Dyax Corp.  Additional
 information about Zyomyx can be obtained at http://www.zyomyx.com .
     This release contains forward-looking statements that are subject to risks
 and uncertainties that could cause actual results to differ materially from
 those set forth in the forward-looking statements.  Actual results may differ
 materially from those projected.  These forward-looking statements represent
 the Company's judgement as of the date of this release.  The Company
 disclaims, however, any intent or obligation to update these forward-looking
 statements.
 
     NOTE:  Zyomyx is a trademark of Zyomyx, Inc.  All other trademarks are the
 property of their registered owners.
 
 

SOURCE Zyomyx, Inc.
    HAYWARD, Calif., April 3 /PRNewswire/ -- Zyomyx, Inc. announced today the
 appointment of Raju Kucherlapati, Ph.D., to its Board of Directors.
     Since 1989, Dr. Kucherlapati has served as Chairman of the Department of
 Molecular Genetics at the Albert Einstein College of Medicine.  In 1993,
 Dr. Kucherlapati assumed additional responsibility as Director of the
 college's Human Genetics Program, which seeks to bring the power of molecular
 genetics to the scientific community.  From 1982 to 1989, Dr. Kucherlapati was
 a Professor at the University of Illinois College of Medicine.  Prior to this
 post, Dr. Kucherlapati served as an Assistant Professor at Princeton
 University.  During his 30-year career as a geneticist, Dr. Kucherlapati has
 participated in the human genome mapping and sequencing effort, contributed to
 the sequencing of the mouse genome and worked to identify genes key to human
 genetic disorders.  He also serves as a member of the National Advisory
 Council of the National Human Genome Research Institute.  Dr. Kucherlapati
 completed his postdoctoral work at Yale University and was awarded a Ph.D. in
 Genetics from the University of Illinois, Urbana.
     Dr. Kucherlapati was a founder of Cell Genesys, Inc. and Millennium
 Pharmaceuticals, Inc., and currently serves as a Director for Abgenix, Inc.,
 Millennium, and Valentis, Inc.  Through a combination of his own research and
 his affiliations with these companies, Dr. Kucherlapati has contributed
 greatly to a number of key advancements in biotechnology and has participated
 in successfully guiding several emerging companies to industry leadership.
     "We are delighted to welcome Dr. Kucherlapati to our Board of Directors,"
 stated Lawrence K. Cohen, Ph.D., Chief Executive Officer of Zyomyx.
 "Dr. Kucherlapati's experience with leading life science companies will assist
 the Company's growth and strengthen its position within the proteomics
 community.  In addition, his expertise in the area of genomics and with the
 technical innovations that advanced that field will provide critical guidance
 as Zyomyx seeks to pioneer new technologies for protein research."
     Located in Hayward, California, Zyomyx, Inc., is bridging the gap between
 genomic information and proteomics through the development of a versatile
 platform technology to innovate protein analysis.  Zyomyx' approach will, for
 the first time, bring to proteomics highly parallel and high throughput
 analysis, capacities that are essential to the advancement of genomics. Zyomyx
 has successfully integrated protein biochemistry with advanced materials
 science and microfabrication to create the first miniaturized biochip
 containing high-density arrays of functional proteins for use in drug
 discovery and diagnosis.  Zyomyx' lead product, the Proteomics Biochip, a
 protein profiling biochip, is designed to accelerate target discovery and
 validation, and has applications throughout the pharmaceutical drug
 development process.  Zyomyx has ongoing partnerships with Fujirebio, Inc.,
 Cambridge Antibody Technology, MDS Proteomics Inc. and Dyax Corp.  Additional
 information about Zyomyx can be obtained at http://www.zyomyx.com .
     This release contains forward-looking statements that are subject to risks
 and uncertainties that could cause actual results to differ materially from
 those set forth in the forward-looking statements.  Actual results may differ
 materially from those projected.  These forward-looking statements represent
 the Company's judgement as of the date of this release.  The Company
 disclaims, however, any intent or obligation to update these forward-looking
 statements.
 
     NOTE:  Zyomyx is a trademark of Zyomyx, Inc.  All other trademarks are the
 property of their registered owners.
 
 SOURCE  Zyomyx, Inc.